Rose H Dicovitsky, Jill T Schappa, Ashley J Schulte, Haeree P Lang, Ellen Kuerbitz, Sarah Roberts, Taylor A DePauw, Mitzi Lewellen, Amber L Winter, Kathy Stuebner, Michelle Buettner, Kelly Reid, Kelly Bergsrud, Sara Pracht, Andrea Chehadeh, Caitlin Feiock, M Gerard O'Sullivan, Tim Carlson, Alexandra R Armstrong, Danielle Meritet, Michael S Henson, Brenda J Weigel, Jaime F Modiano, Antonella Borgatti, Daniel A Vallera
EGFR-targeted therapies are efficacious, but toxicity is common and can be severe. Urokinase type plasminogen activator receptor (uPAR)-targeted drugs are only emerging, so neither their efficacy nor toxicity is fully established. Recombinant eBAT was created by combining cytokines EGF and uPA on the same single-chain molecule with truncated Pseudomonas toxin. Its purpose was to simultaneously target tumors and their vasculature in the tumor microenvironment. In prior studies on mice and dogs, the drug proved efficacious...
August 26, 2024: Toxins